Background Irinotecan hydrochloride, a topoisomerase I inhibitor,is effective against small-cell lung cancer. In a phase 2 studyof irinotecan plus cisplatin in patients with extensive small-celllung cancer, there was a high response rate and a promisingmedian survival time.
Methods We conducted a multicenter, randomized, phase 3 studyin which we compared irinotecan plus cisplatin with etoposideplus cisplatin in patients with extensive (metastatic) small-celllung cancer.
Results The planned size of the study population was 230 patients,but enrollment was terminated early because an interim analysisfound a statistically significant difference in survival betweenthe patients assigned to receive irinotecan and cisplatin andthose assigned to receive etoposide and cisplatin; as a result,only 154 patients were enrolled. The median survival was 12.8months in the irinotecan-plus-cisplatin group and 9.4 monthsin the etoposide-plus-cisplatin group (P=0.002 by the unadjustedlog-rank test). At two years, the proportion of patients survivingwas 19.5 percent in the irinotecan-plus-cisplatin group and5.2 percent in the etoposide-plus-cisplatin group. Severe orlife-threatening myelosuppression was more frequent in the etoposide-plus-cisplatingroup than in the irinotecan-plus-cisplatin group, and severeor life-threatening diarrhea was more frequent in the irinotecan-plus-cisplatingroup than in the etoposide-plus-cisplatin group.
Conclusions Irinotecan plus cisplatin is an effective treatmentfor metastatic small-cell lung cancer.
Source Information
From Kanagawa Cancer Center, Yokohama (K.N.); National Cancer Center Hospital East, Chiba (Y.N.); National Kinki Central Hospital for Chest Diseases, Osaka (M.K.); Osaka City General Hospital, Osaka (S.N.); Aichi Cancer Center, Nagoya (T.S.); Niigata Cancer Center Hospital, Niigata (A.Y.); Kinki University School of Medicine, Osaka (M.F.); Tochigi Cancer Center, Tochigi (K.M.); Yokohama Municipal Citizen's Hospital, Yokohama (K.W.); National Cancer Center Central Hospital, Tokyo (T.T., N.S.); and the Cancer Information and Epidemiology Division, National Cancer Center Research Institute, Tokyo (S.Y.) — all in Japan.
Address reprint requests to Dr. Saijo at the National Cancer Center, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan, or at nsaijo{at}ncc.go.jp.
Trotta, F., Apolone, G., Garattini, S., Tafuri, G.
(2008). Stopping a trial early in oncology: for patients or for industry?. Ann Oncol
19: 1347-1353
[Abstract][Full Text]
Chin, K., Baba, S., Hosaka, H., Ishiyama, A., Mizunuma, N., Shinozaki, E., Suenaga, M., Kozuka, T., Seto, Y., Yamamoto, N., Hatake, K.
(2008). Irinotecan Plus Cisplatin for Therapy of Small-cell Carcinoma of the Esophagus: Report of 12 Cases from Single Institution Experience. Jpn J Clin Oncol
0: hyn041v1-6
[Abstract][Full Text]
Leyvraz, S., Pampallona, S., Martinelli, G., Ploner, F., Perey, L., Aversa, S., Peters, S., Brunsvig, P., Montes, A., Lange, A., Yilmaz, U., Rosti, G., On behalf of the Solid Tumors Working Party of the,
(2008). A Threefold Dose Intensity Treatment With Ifosfamide, Carboplatin, and Etoposide for Patients With Small Cell Lung Cancer: A Randomized Trial. JNCI J Natl Cancer Inst
100: 533-541
[Abstract][Full Text]
Ku, G. Y., Minsky, B. D., Rusch, V. W., Bains, M., Kelsen, D. P., Ilson, D. H.
(2008). Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience. Ann Oncol
19: 533-537
[Abstract][Full Text]
Ramsay, E. C., Anantha, M., Zastre, J., Meijs, M., Zonderhuis, J., Strutt, D., Webb, M. S., Waterhouse, D., Bally, M. B.
(2008). Irinophore C: A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy against a Panel of Human Xenograft Tumors. Clin. Cancer Res.
14: 1208-1217
[Abstract][Full Text]
Lee, D. H., Kim, S.-W., Suh, C., Lee, J.-S., Lee, J. H., Lee, S.-J., Ryoo, B. Y., Park, K., Kim, J. S., Heo, D. S., Kim, N. K.
(2008). Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study. Ann Oncol
19: 123-127
[Abstract][Full Text]
Lee, D. H., Kim, S.-W., Bae, K.-S., Hong, J.-S., Suh, C., Kang, Y.-K., Lee, J.-S.
(2007). A Phase I and Pharmacologic Study of Belotecan in Combination with Cisplatin in Patients with Previously Untreated Extensive-Stage Disease Small Cell Lung Cancer. Clin. Cancer Res.
13: 6182-6186
[Abstract][Full Text]
Socinski, M. A., Bogart, J. A.
(2007). Limited-Stage Small-Cell Lung Cancer: The Current Status of Combined-Modality Therapy. JCO
25: 4137-4145
[Abstract][Full Text]
Simon, G. R., Turrisi, A.
(2007). Management of Small Cell Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition). Chest
132: 324S-339S
[Abstract][Full Text]
Lally, B. E., Urbanic, J. J., Blackstock, A. W., Miller, A. A., Perry, M. C.
(2007). Small Cell Lung Cancer: Have We Made Any Progress Over the Last 25 Years?. The Oncologist
12: 1096-1104
[Abstract][Full Text]
Fujiwara, Y., Sekine, I., Tsuta, K., Ohe, Y., Kunitoh, H., Yamamoto, N., Nokihara, H., Yamada, K., Tamura, T.
(2007). Effect of Platinum Combined with Irinotecan or Paclitaxel against Large Cell Neuroendocrine Carcinoma of the Lung. Jpn J Clin Oncol
0: hym053v1-18
[Abstract][Full Text]
Yamazaki, K., Boku, N., Shibamoto, K., Yasui, H., Fukutomi, A., Yoshino, T., Hironaka, S., Onozawa, Y., Otake, Y., Hasuike, N., Matsubayashi, H., Inui, T., Yamaguchi, Y., Ono, H.
(2007). The Role of the Outpatient Clinic in Chemotherapy for Patients with Unresectable or Recurrent Gastric Cancer. Jpn J Clin Oncol
37: 96-101
[Abstract][Full Text]
Seifart, U, Fink, T, Schade-Brittinger, C, Hans, K, Mueller, C, Koschel, G, Schroeder, H, Lorenz, R, Dethling, J, Wolf, M
(2007). Randomised phase II study comparing topotecan/carboplatin administration for 5 versus 3 days in the treatment of extensive-stage small-cell lung cancer. Ann Oncol
18: 104-109
[Abstract][Full Text]
Saito, H., Takada, Y., Ichinose, Y., Eguchi, K., Kudoh, S., Matsui, K., Nakagawa, K., Takada, M., Negoro, S., Tamura, K., Ando, M., Tada, T., Fukuoka, M.
(2006). Phase II Study of Etoposide and Cisplatin With Concurrent Twice-Daily Thoracic Radiotherapy Followed by Irinotecan and Cisplatin in Patients With Limited-Disease Small-Cell Lung Cancer: West Japan Thoracic Oncology Group 9902. JCO
24: 5247-5252
[Abstract][Full Text]
Takigawa, N., Kiura, K., Tabata, M., Tanimoto, M.
(2006). Fractionated Administration of Irinotecan and Cisplatin in Japanese Patients With Extensive-Stage-Disease Small-Cell Lung Cancer. JCO
24: 5175-5175
[Full Text]
Hanna, N. H.
(2006). In Reply. JCO
24: 5175-5176
[Full Text]
Chien, C.-R., Lai, M.-S.
(2006). Trends in the pattern of care for lung cancer and their correlation with new clinical evidence: experiences in a university-affiliated medical center.. American Journal of Medical Quality
21: 408-414
[Abstract]
Socinski, M. A., Weissman, C., Hart, L. L., Beck, J. T., Choksi, J. K., Hanson, J. P., Prager, D., Monberg, M. J., Ye, Z., Obasaju, C. K.
(2006). Randomized Phase II Trial of Pemetrexed Combined With Either Cisplatin or Carboplatin in Untreated Extensive-Stage Small-Cell Lung Cancer. JCO
24: 4840-4847
[Abstract][Full Text]
Hainsworth, J. D., Spigel, D. R., Litchy, S., Greco, F. A.
(2006). Phase II Trial of Paclitaxel, Carboplatin, and Etoposide in Advanced Poorly Differentiated Neuroendocrine Carcinoma: A Minnie Pearl Cancer Research Network Study. JCO
24: 3548-3554
[Abstract][Full Text]
Smith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., Demetri, G., Desch, C. E., Pizzo, P. A., Schiffer, C. A., Schwartzberg, L., Somerfield, M. R., Somlo, G., Wade, J. C., Wade, J. L., Winn, R. J., Wozniak, A. J., Wolff, A. C.
(2006). 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. JCO
24: 3187-3205
[Abstract][Full Text]
Schaaf, L. J., Hammond, L. A., Tipping, S. J., Goldberg, R. M., Goel, R., Kuhn, J. G., Miller, L. L., Compton, L. D., Cisar, L. A., Elfring, G. L., Gruia, G., McGovren, J. P., Pirotta, N., Yin, D., Sharma, A., Duncan, B. A., Rothenberg, M. L.
(2006). Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.. Clin. Cancer Res.
12: 3782-3791
[Abstract][Full Text]
Perry, M. C.
(2006). Reponses to Topoisomerase-I Inhibitors in Extensive Small-Cell Lung Cancer: Chance or Chromosomes?. JCO
24: 1980-1981
[Full Text]
Hanna, N., Bunn, P. A. Jr, Langer, C., Einhorn, L., Guthrie, T. Jr, Beck, T., Ansari, R., Ellis, P., Byrne, M., Morrison, M., Hariharan, S., Wang, B., Sandler, A.
(2006). Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer. JCO
24: 2038-2043
[Abstract][Full Text]
Schmittel, A., von Weikersthal, L. F., Sebastian, M., Martus, P., Schulze, K., Hortig, P., Reeb, M., Thiel, E., Keilholz, U.
(2006). A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol
17: 663-667
[Abstract][Full Text]
Arakawa, Y., Suzuki, H., Saito, S., Yamada, H.
(2006). Novel missense mutation of the DNA topoisomerase I gene in SN-38-resistant DLD-1 cells.. Molecular Cancer Therapeutics
5: 502-508
[Abstract][Full Text]
Thatcher, N., Qian, W., Clark, P. I., Hopwood, P., Sambrook, R. J., Owens, R., Stephens, R. J., Girling, D. J.
(2005). Ifosfamide, Carboplatin, and Etoposide With Midcycle Vincristine Versus Standard Chemotherapy in Patients With Small-Cell Lung Cancer and Good Performance Status: Clinical and Quality-of-Life Results of the British Medical Research Council Multicenter Randomized LU21 Trial. JCO
23: 8371-8379
[Abstract][Full Text]
Greco, F. A., Thompson, D. S., Morrissey, L. H., Erland, J. B., Burris, H. A. III, Spigel, D. R., Joseph, G., Corso, S. W., Spremulli, E., Hainsworth, J. D.
(2005). Paclitaxel/Carboplatin/Etoposide Versus Paclitaxel/Topotecan for Extensive-Stage Small Cell Lung Cancer: A Minnie Pearl Cancer Research Network Randomized, Prospective Phase II Trial. The Oncologist
10: 728-733
[Abstract][Full Text]
Kubota, K., Nishiwaki, Y., Sugiura, T., Noda, K., Mori, K., Kawahara, M., Negoro, S., Watanabe, K., Imamura, F., Tamura, T., Saijo, N.
(2005). Pilot Study of Concurrent Etoposide and Cisplatin Plus Accelerated Hyperfractionated Thoracic Radiotherapy Followed by Irinotecan and Cisplatin for Limited-Stage Small Cell Lung Cancer: Japan Clinical Oncology Group 9903. Clin. Cancer Res.
11: 5534-5538
[Abstract][Full Text]
Han, J.-Y., Cho, K. H., Lee, D. H., Kim, H. Y., Kim, E.-A, Lee, S. Y., Lee, J. S.
(2005). Phase II Study of Irinotecan Plus Cisplatin Induction Followed by Concurrent Twice-Daily Thoracic Irradiation With Etoposide Plus Cisplatin Chemotherapy for Limited-Disease Small-Cell Lung Cancer. JCO
23: 3488-3494
[Abstract][Full Text]
Sakai, M., Ishikawa, S., Yamamoto, T., Onizuka, M., Sakakibara, Y., Iijima, T., Noguchi, M.
(2005). Preoperative TNM evaluation of peripheral clinical stage I small cell lung cancer treated by initial lobectomy with adjuvant chemotherapy. ICVTS
4: 118-122
[Abstract][Full Text]
Ohe, Y., Negoro, S., Matsui, K., Nakagawa, K., Sugiura, T., Takada, Y., Nishiwaki, Y., Yokota, S., Kawahara, M., Saijo, N., Fukuoka, M., Ariyoshi, Y., On behalf of the Amrubicin SCLC Study Group,
(2005). Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer. Ann Oncol
16: 430-436
[Abstract][Full Text]
Warshamana-Greene, G. S., Litz, J., Buchdunger, E., Garcia-Echeverria, C., Hofmann, F., Krystal, G. W.
(2005). The Insulin-Like Growth Factor-I Receptor Kinase Inhibitor, NVP-ADW742, Sensitizes Small Cell Lung Cancer Cell Lines to the Effects of Chemotherapy. Clin. Cancer Res.
11: 1563-1571
[Abstract][Full Text]
Michael, M., Doherty, M.M.
(2005). Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy. JCO
23: 205-229
[Abstract][Full Text]
Tamborini, E., Bonadiman, L., Negri, T., Greco, A., Staurengo, S., Bidoli, P., Pastorino, U., Pierotti, M. A., Pilotti, S.
(2004). Detection of Overexpressed and Phosphorylated Wild-Type Kit Receptor in Surgical Specimens of Small Cell Lung Cancer. Clin. Cancer Res.
10: 8214-8219
[Abstract][Full Text]
Stewart, D. J.
(2004). Topotecan in the First-Line Treatment of Small Cell Lung Cancer. The Oncologist
9: 33-42
[Abstract][Full Text]
Schmittel, A., Jahnke, K., Thiel, E., Keilholz, U.
(2004). Neomycin as secondary prophylaxis for irinotecan-induced diarrhea. Ann Oncol
15: 1296-1296
[Full Text]
Neubauer, M., Schwartz, J., Caracandas, J., Conkling, P., Ilegbodu, D., Tuttle, T., Asmar, L.
(2004). Results of a Phase II Study of Weekly Paclitaxel Plus Carboplatin in Patients With Extensive Small-Cell Lung Cancer With Eastern Cooperative Oncology Group Performance Status of 2, or Age >= 70 Years. JCO
22: 1872-1877
[Abstract][Full Text]
Kim, J. H., Lee, S.-H., Park, J., Kim, H. Y., Lee, S. I., Nam, E. M., Park, J.-O., Kim, K., Jung, C. W., Im, Y.-H., Kang, W. K., Lee, M. H., Park, K.
(2004). Extrapulmonary Small-cell Carcinoma: a Single-institution Experience. Jpn J Clin Oncol
34: 250-254
[Abstract][Full Text]
Ramalingam, S., Belani, C. P., Day, R., Zamboni, B. A., Jacobs, S. A., Jett, J. R.
(2004). Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer. Ann Oncol
15: 247-251
[Abstract][Full Text]
Wagner, L. M., Crews, K. R., Iacono, L. C., Houghton, P. J., Fuller, C. E., McCarville, M. B., Goldsby, R. E., Albritton, K., Stewart, C. F., Santana, V. M.
(2004). Phase I Trial of Temozolomide and Protracted Irinotecan in Pediatric Patients with Refractory Solid Tumors. Clin. Cancer Res.
10: 840-848
[Abstract][Full Text]
Spira, A., Ettinger, D. S.
(2004). Multidisciplinary Management of Lung Cancer. NEJM
350: 379-392
[Full Text]
Edelman, M. J., Chansky, K., Gaspar, L. E., Leigh, B., Weiss, G. R., Taylor, S. A., Crowley, J., Livingston, R., Gandara, D. R.
(2004). Phase II Trial of Cisplatin/Etoposide and Concurrent Radiotherapy Followed by Paclitaxel/Carboplatin Consolidation for Limited Small-Cell Lung Cancer: Southwest Oncology Group 9713. JCO
22: 127-132
[Abstract][Full Text]
Inoue, A., Saijo, Y., Kikuchi, T., Gomi, K., Suzuki, T., Maemondo, M., Miki, M., Sato, T., Nukiwa, T.
(2004). Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis. Ann Oncol
15: 51-54
[Abstract][Full Text]
Pardo, O. E., Lesay, A., Arcaro, A., Lopes, R., Ng, B. L., Warne, P. H., McNeish, I. A., Tetley, T. D., Lemoine, N. R., Mehmet, H., Seckl, M. J., Downward, J.
(2003). Fibroblast Growth Factor 2-Mediated Translational Control of IAPs Blocks Mitochondrial Release of Smac/DIABLO and Apoptosis in Small Cell Lung Cancer Cells. Mol. Cell. Biol.
23: 7600-7610
[Abstract][Full Text]
Hurria, A., Kris, M. G.
(2003). Management of Lung Cancer in Older Adults. CA Cancer J Clin
53: 325-341
[Abstract][Full Text]
Felip, E., Rosell, R., Domine, M., Santome, L., Garrido, P., Font, A., Carrato, A., Terrasa, J., Vadell, C., Mane, J. M., Baselga, J.
(2003). Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study. Ann Oncol
14: 1549-1554
[Abstract][Full Text]
Litz, J., Carlson, P., Warshamana-Greene, G. S., Grant, S., Krystal, G. W.
(2003). Flavopiridol Potently Induces Small Cell Lung Cancer Apoptosis during S Phase in a Manner That Involves Early Mitochondrial Dysfunction. Clin. Cancer Res.
9: 4586-4594
[Abstract][Full Text]
Hoskins, P.J., Swenerton, K.D., Pike, J.A., Lim, P., Aquino-Parsons, C., Wong, F., Lee, N.
(2003). Small-Cell Carcinoma of the Cervix: Fourteen Years of Experience at a Single Institution Using a Combined-Modality Regimen of Involved-Field Irradiation and Platinum-Based Combination Chemotherapy. JCO
21: 3495-3501
[Abstract][Full Text]
Laskin, J., Sandler, A., Johnson, D. H.
(2003). An Advance in Small-Cell Lung Cancer Treatment--More or Less. JNCI J Natl Cancer Inst
95: 1099-1101
[Full Text]
Booton, R, Jones, M, Thatcher, N
(2003). Lung cancer * 7: Management of lung cancer in elderly patients. Thorax
58: 711-720
[Full Text]
Kawabata, S., Oka, M., Soda, H., Shiozawa, K., Nakatomi, K., Tsurutani, J., Nakamura, Y., Doi, S., Kitazaki, T., Sugahara, K., Yamada, Y., Kamihira, S., Kohno, S.
(2003). Expression and Functional Analyses of Breast Cancer Resistance Protein in Lung Cancer. Clin. Cancer Res.
9: 3052-3057
[Abstract][Full Text]
Furuta, T., Takemura, H., Liao, Z.-Y., Aune, G. J., Redon, C., Sedelnikova, O. A., Pilch, D. R., Rogakou, E. P., Celeste, A., Chen, H. T., Nussenzweig, A., Aladjem, M. I., Bonner, W. M., Pommier, Y.
(2003). Phosphorylation of Histone H2AX and Activation of Mre11, Rad50, and Nbs1 in Response to Replication-dependent DNA Double-strand Breaks Induced by Mammalian DNA Topoisomerase I Cleavage Complexes. J. Biol. Chem.
278: 20303-20312
[Abstract][Full Text]
Sekine, I., Nishiwaki, Y., Noda, K., Kudoh, S., Fukuoka, M., Mori, K., Negoro, S., Yokoyama, A., Matsui, K., Ohsaki, Y., Nakano, T., Saijo, N.
(2003). Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI). Ann Oncol
14: 709-714
[Abstract][Full Text]
Licitra, E. J., Vyas, V., Nelson, K., Musanti, R., Beers, S., Thomas, C., Poplin, E., Smith, S., Lin, Y., Schaaf, Larry. J., Aisner, J., Gounder, M., Rajendra, R., Saleem, A., Toppmeyer, D., Rubin, E. H.
(2003). Phase I Evaluation of Sequential Topoisomerase Targeting with Irinotecan/Cisplatin Followed by Etoposide in Patients with Advanced Malignancy. Clin. Cancer Res.
9: 1673-1679
[Abstract][Full Text]
Souid, A.-K., Dubowy, R. L., Blaney, S. M., Hershon, L., Sullivan, J., McLeod, W. D., Bernstein, M. L.
(2003). Phase I Clinical and Pharmacologic Study of Weekly Cisplatin and Irinotecan Combined with Amifostine for Refractory Solid Tumors. Clin. Cancer Res.
9: 703-710
[Abstract][Full Text]
Ardizzoni, A., Manegold, C., Debruyne, C., Gaafar, R., Buchholz, E., Smit, E. F., Lianes, P., ten Velde, G., Bosquee, L., Legrand, C., Neumaier, C., King, K.
(2003). European Organization for Research and Treatment of Cancer (EORTC) 08957 Phase II Study of Topotecan in Combination with Cisplatin as Second-Line Treatment of Refractory and Sensitive Small Cell Lung Cancer. Clin. Cancer Res.
9: 143-150
[Abstract][Full Text]
Simon, G. R., Wagner, H.
(2003). Small Cell Lung Cancer. Chest
123: 259S-271S
[Abstract][Full Text]
Sundstrom, S., Bremnes, R. M., Kaasa, S., Aasebo, U., Hatlevoll, R., Dahle, R., Boye, N., Wang, M., Vigander, T., Vilsvik, J., Skovlund, E., Hannisdal, E., Aamdal, S.
(2002). Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years' Follow-Up. JCO
20: 4665-4672
[Abstract][Full Text]
Xu, Y., Villalona-Calero, M. A.
(2002). Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol
13: 1841-1851
[Abstract][Full Text]
Spiro, S. G., Porter, J. C.
(2002). Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment. Am. J. Respir. Crit. Care Med.
166: 1166-1196
[Abstract][Full Text]
Machtay, M.
(2002). The Early Rad Catches the Tumor?. JCO
20: 3045-3047
[Full Text]
Ando, Y., Figg, W. D., Noda, K., Saijo, N.
(2002). Irinotecan in Small-Cell Lung Cancer. NEJM
346: 1414-1415
[Full Text]
(2002). Chemotherapy for Lung Cancer. JWatch General
2002: 1-1
[Full Text]
Carney, D. N.
(2002). Lung Cancer -- Time to Move on from Chemotherapy. NEJM
346: 126-128
[Full Text]
Previous
